Regression of metastatic non-small-cell lung cancer in a chemonaive patient treated with gefitinib ('Iressa', ZD1839)

被引：0
|
作者：
Petruzelka, L [1 ]
Zemanova, M [1 ]
机构：
[1] Charles Univ Prague, Univ Hosp, Prague, Czech Republic
来源：
BRITISH JOURNAL OF CANCER | 2003年 / 89卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S32 / S32
页数：1
相关论文
共 50 条
  • [31] Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, 'Iressa') on an expanded access study
    Dongiovanni, Vincenzo
    Dongiovanni, Diego
    Buffoni, Lucio
    Barone, Carla
    Fissore, Camilla
    Addeo, Alfredo
    Larovere, Erika
    Grillo, Raffaella
    Nuzzolo, Gloria
    Schena, Marina
    Bertetto, Oscar
    ANNALS OF ONCOLOGY, 2005, 16 : 21 - 22
  • [32] Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib (Iressa, ZD1839)
    Kakiuchi, S
    Daigo, Y
    Ishikawa, N
    Furukawa, C
    Tsunoda, T
    Yano, S
    Nakagawa, K
    Tsuruo, T
    Kohno, N
    Fukuoka, M
    Sone, S
    Nakamura, Y
    HUMAN MOLECULAR GENETICS, 2004, 13 (24) : 3029 - 3043
  • [33] Gefitinib ('Iressa', ZD1839) in heavily pretreated non-small-cell lung cancer patients: a case series report from the 'Iressa' Expanded Access Programme
    Gridelli, C
    Rossi, A
    Maione, P
    Musto, L
    Del Gaizo, F
    Airoma, G
    BRITISH JOURNAL OF CANCER, 2003, 89 : S29 - S29
  • [34] Gefitinib ('IRESSA', ZD1839) in patients with non-small cell lung cancer (NSCLC): The Royal Marsden experience
    Maisey, NR
    Parton, M
    Harper-Wynne, C
    Sumpter, K
    Ashley, S
    Eisen, T
    O'Brien, M
    BRITISH JOURNAL OF CANCER, 2004, 91 : S15 - S15
  • [35] Gefitinib ('Iressa', ZD1839) in elderly patients with progressive pretreated non-small-cell lung cancer: results from the Istituto Clinico Humanitas
    Parra, HS
    Cavina, R
    Zucali, P
    Campagnoli, E
    Latteri, F
    Biancofiore, G
    Abbadessa, G
    Morenghi, E
    Santoro, A
    BRITISH JOURNAL OF CANCER, 2003, 89 : S33 - S33
  • [36] Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib (‘Iressa’, ZD1839) in non-small-cell lung cancer
    H S Parra
    R Cavina
    F Latteri
    P A Zucali
    E Campagnoli
    E Morenghi
    G C Grimaldi
    M Roncalli
    A Santoro
    British Journal of Cancer, 2004, 91 : 208 - 212
  • [37] Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib ('Iressa', ZD1839) in non-small-cell lung cancer
    Parra, HS
    Cavina, R
    Latteri, F
    Zucali, PA
    Campagnoli, E
    Morenghi, E
    Grimaldi, GC
    Roncalli, M
    Santoro, A
    BRITISH JOURNAL OF CANCER, 2004, 91 (02) : 208 - 212
  • [38] Correlation between epidermal growth factor receptor expression and tumour response in patients with advanced non-small-cell lung cancer treated with gefitinib ('Iressa', ZD1839)
    de Braud, F
    Noberasco, C
    Curigliano, G
    De Pas, M
    Dodaro, L
    Manzoni, S
    Milani, A
    Rocca, A
    Ferrucci, F
    Ferretti, G
    Pelosi, G
    BRITISH JOURNAL OF CANCER, 2003, 89 : S27 - S27
  • [39] ZD1839 (Iressa™):: For more than just non-small cell lung cancer
    Ranson, M
    ONCOLOGIST, 2002, 7 : 16 - 24
  • [40] Cell growth after withdrawal of gefitinib ('Iressa', ZD1839) in human lung cancer cells
    Satoh, H
    Ishikawa, H
    Nakayama, M
    Fujiwara, M
    Ohtsuka, M
    Sekizawa, K
    ONCOLOGY REPORTS, 2004, 12 (03) : 615 - 619
12345